Halcion

Halcion is a prescription oral tablet that contains the benzodiazepine triazolam. Marketed in the EU without a listed strength, it is classified as a Schedule IV controlled substance. As a sedative‑hypnotic, Halcion enhances GABA‑A receptor activity to promote sleep and is intended for short‑term treatment of insomnia. The tablet is taken by mouth under the guidance of a healthcare professional, according to the prescribing information provided.

Halcion (triazolam) is primarily indicated for the short‑term management of insomnia in adults when other non‑pharmacologic measures have been insufficient.

- Short‑term treatment of difficulty falling asleep. - Short‑term treatment of difficulty staying asleep. - Use in patients who require rapid onset of sleep. - May be considered when behavioral therapy is not effective. - Typically prescribed for a limited number of nights to reduce dependence risk.

The side‑effect profile of Halcion reflects its benzodiazepine class and includes both common, usually mild reactions and less frequent, potentially serious events.

Common: - Drowsiness or fatigue, especially after the first dose. - Dizziness or light‑headed feeling. - Headache ranging from mild to moderate intensity. - Impaired coordination or unsteady gait. - Short‑term memory disturbances, often anterograde amnesia. - Unpleasant taste or metallic sensation in the mouth.

Serious: - Respiratory depression, particularly when combined with other depressants. - Severe allergic reaction, including rash, swelling, or difficulty breathing. - Paradoxical agitation, aggression, or anxiety. - Visual or auditory hallucinations and psychotic symptoms. - Development of physical dependence or withdrawal symptoms after prolonged use.

When prescribing Halcion, clinicians consider several precautions to minimize risks and ensure safe use.

- Limit use to short durations, typically not exceeding two weeks. - Assess patient history for substance abuse or dependence. - Use caution in elderly patients due to increased sensitivity and fall risk. - Avoid use during pregnancy; triazolam is classified as Category D. - Monitor for signs of depression or suicidal thoughts. - Adjust dose in patients with hepatic impairment. - Do not operate heavy machinery or drive until the drug’s effects are known.

Halcion can interact with a variety of medications, affecting its sedative effect or increasing adverse reactions.

Avoid: - Other central nervous system depressants such as opioids, barbiturates, or alcohol. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin). - Medications that significantly prolong QT interval. - CNS stimulants that may counteract sedative effect (e.g., caffeine, pseudoephedrine).

Use with caution: - Antidepressants, especially SSRIs and SNRIs. - Antihistamines and over‑the‑counter sleep aids containing diphenhydramine. - Anticonvulsants that are metabolized by CYP3A4 (e.g., carbamazepine). - Herbal supplements such as St. John’s wort that induce CYP3A4.